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Abstract 
 
Camel milk (CM) has been reported to have anti-diabetic properties in many in vitro 
and in vivo studies but the molecular basis of such beneficial properties are still elusive. 
Recently, camel milk whey proteins (CWPs) have been shown to positively affect the 
activity of the human insulin receptor (hIR) in cell lines. In this study, we profiled 
crude CWPs and their hydrolysates as well as camel milk lactoferrin (CMLF) for their 
pharmacological and functional effects on hIR activity and its downstream signaling 
in both human embryonic kidney (HEK293) and hepatocarcinoma (HepG2) cell lines. 
For this, bioluminescence resonance energy transfer (BRET) technology was used to 
assess hIR activity in live cells and the phosphorylation status of the downstream 
protein kinase B (Akt) and the extracellular signal-regulated kinases (ERK1/2) was 
also analyzed in parallel. Moreover, glucose uptake was examined in order to link our 
data to more integrated cell response and to the hypoglycemic effects of camel milk. 
Our data clearly demonstrate the biological activity of CWPs, their hydrolysates, and 
CMLF, by promoting Akt and ERK1/2 phosphorylation in both HEK293 and HepG2 
cells. In addition, our BRET assay confirmed the positive pharmacological action of 
CWPs and their hydrolysates on hIR activity in a dose-dependent manner. More 
interestingly, the combination of CWPs and their hydrolysates with insulin revealed 
an allosteric modulation of hIR that was drastically abolished by the competitive hIR-
selective peptide antagonist S961. This clearly demonstrates the implication of hIR 
activation in the effects of CWPs and their hydrolysates. Finally, such effects on BRET 
data and kinase phosphorylation were clearly correlated with an increase in glucose 
uptake in HepG2 cells. Our data reveal the pharmacological effects of camel milk 
proteins on hIR activity and function. This provides for the first time the molecular 
basis of the anti-diabetic properties of camel milk that was unknown until now. 
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 )cibarA ni( tcartsbA dna eltiT
 
 دراﺳﺔ ﺗﺄﺛﯿﺮ ﺑﺮوﺗﯿﻨﺎت ﺣﻠﯿﺐ اﻹﺑﻞ ﻋﻠﻰ وظﯿﻔﺔ ﻣﺴﺘﻘﺒﻼت ھﺮﻣﻮن اﻹﻧﺴﻮﻟﯿﻦ
 ﺺاﻟﻤﻠﺨ
ا ﻛﻤﻀﺎد ﻟﻠﺴﻜﺮي، ﻟﻜﻦ ھﺬ )RIh(أن ﺣﻠﯿﺐ اﻹﺑﻞ ﻟﮫ ﺗﺄﺛﯿﺮ ﻋﻠﻰ ھﺮﻣﻮن اﻹﻧﺴﻮﻟﯿﻦأظﮭﺮت ﻋﺪة دراﺳﺎت 
)اﻟﻤﺴﺎرات اﻟﻤﻮﺟﻮدة داﺧﻞ  ﻋﻠﻰ ﻣﺴﺘﻮى اﻟﺒﯿﻮﻟﻮﺟﯿﺎ اﻟﺠﺰﯾﺌﯿﺔ ﻏﯿﺮ واﺿﺢ ﺣﺘﻰ اﻵن ﻞﺤﻠﯿﺐ اﻹﺑاﻟﺘﺄﺛﯿﺮ ﻟ
 وأﺟﺰاءه )sPWC(وﺟﺪت دراﺳﺔ أن ﺑﺮوﺗﯿﻨﺎت ﺣﻠﯿﺐ اﻹﺑﻞ ﻣﺜﻞ ﺑﺮوﺗﯿﻦ ﻣﺼﻞ اﻟﻠﺒﻦ ،اﻟﺨﻠﯿﺔ(. ﺣﺪﯾﺜﺎ ً 
ﻟﮭﺎ ﺗﺄﺛﯿﺮ إﯾﺠﺎﺑﻲ ﻋﻠﻰ زﯾﺎدة  ، )FLMC(ﻦﻻ ﻛﺘﻮﻓﺮﯾإﻟﻰ ﺑﺮوﺗﯿﻦ  ﺑﺎﻹﺿﺎﻓﺔ )setasylordyh sPWC(
ﺗﻤﺖ ﺗﻨﻘﯿﺔ اﻟﺒﺮوﺗﯿﻨﺎت اﻟﺘﻲ ذُﻛﺮت ﺳﺎﺑﻘﺎ ً ،دراﺳﺘﻨﺎ ھﺬه لاﻹﻧﺴﺎن. ﺧﻼﻓﻲ ﺧﻼﯾﺎ  اﻷﻧﺴﻮﻟﯿﻦﻧﺸﺎط ﻣﺴﺘﻘﺒﻼت 
ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ دراﺳﺔ  ،ﻣﻦ ﺣﻠﯿﺐ اﻹﺑﻞ وﻣﻌﺎﯾﻨﺔ ﻛﯿﻔﯿﺔ ﺗﺄﺛﯿﺮھﺎ ﻋﻠﻰ وظﯿﻔﺔ وﻧﺸﺎط ﻣﺴﺘﻘﺒﻼت اﻹﻧﺴﻮﻟﯿﻦ
و  2GpeHﺗﺄﺛﯿﺮھﺎ ﻋﻠﻰ اﻟﻤﺴﺘﻮى اﻟﺠﺰﯾﺌﻲ ﻟﻠﺨﻼﯾﺎ ﺑﺎﺳﺘﺨﺪام ﻧﻮﻋﯿﻦ ﻣﻦ اﻟﺨﻼﯾﺎ )ﺧﻼﯾﺎ ﺳﺮطﺎن اﻟﻜﺒﺪ 
ﻟﺘﻘﯿﯿﻢ وظﯿﻔﺔ ﻣﺴﺘﻘﺒﻼت  TERBاﺳﺘَﺨﺪﻣﺖ ﺗﻘﻨﯿﺔ  ،. ﻹﺗﻤﺎم ھﺬه اﻟﺘﺠﺎرب(392KEH) ﺧﻼﯾﺎ اﻟﻜﻠﻰ اﻟﺠﻨﯿﻨﯿﺔ
ﻋﻦ طﺮﯾﻖ  2/1KREو  tkAﻛﻞ ﻣﻦ ﺑﺮوﺗﯿﻦ  ﺗﻘﯿﯿﻢ ﺗﻔﻌﯿﻞ ﻧﺸﺎط إﺿﺎﻓﺔ إﻟﻰ،ﻓﻲ اﻟﺨﻼﯾﺎ اﻟﺤﯿّﺔ اﻷﻧﺴﻮﻟﯿﻦ
ﻣﺎ ﯾﺴﻤﻰ ﺑﺎﻟﻔَﺴﻔَﺘﺔ )أي ارﺗﺒﺎطﮭﻢ ﺑﻔﻮﺳﻔﺎت(. أﯾﻀﺎ ًﻗﯿﺎس ﻣﺴﺘﻮى أﺧﺬ واﺳﺘﯿﻌﺎب اﻟﺨﻼﯾﺎ ﻟﻠﺴﻜﺮ ﻟﻠﺤﺼﻮل 
ﻋﻠﻰ ﺻﻮرة أوﺿﺢ ﻟﺮﺑﻄﮭﺎ ﻣﻊ ﺗﺄﺛﯿﺮ ﺣﻠﯿﺐ اﻹﺑﻞ ﻋﻠﻰ ﺧﻔﺾ اﻟﺴﻜﺮي. دراﺳﺘﻨﺎ أﺛﺒﺘﺖ أن ﺑﺮوﺗﯿﻨﺎت ﻣﺼﻞ 
ﻋﻦ طﺮﯾﻖ ﻣﺎ ﯾﺴﻤﻰ  2/1KREو  tkAﺗﻘﻮم ﻋﻠﻰ ﺗﻔﻌﯿﻞ ﻧﺸﺎط ﻛﻞ ﻣﻦ  ،اﻟﻠﺒﻦ وﻻﻛﺘﻮﻓﺮﯾﻦ ﺑﺤﻠﯿﺐ اﻹﺑﻞ
ﺗﻢ ﺗﺄﻛﯿﺪ اﻟﺘﺄﺛﯿﺮ اﻹﯾﺠﺎﺑﻲ ﻟﺒﺮوﺗﯿﻨﺎت ﻣﺼﻞ  TERBﺑﺎﺳﺘﺨﺪام ﺗﻘﻨﯿﺔ  ،ﺑﺎﻟﻔﺴﻔﺘﺔ. ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ھﺬه اﻟﻨﺘﺎﺋﺞ
اﻋﺘﻤﺎداً ﻋﻠﻰ ﺗﺮاﻛﯿﺰ ﻣﻌﯿﻨﺔ. ﻋﻼوةً ﻋﻠﻰ  اﻷﻧﺴﻮﻟﯿﻦاﻟﻠﺒﻦ وﻻﻛﺘﻮﻓﺮﯾﻦ ﻋﻠﻰ وظﯿﻔﺔ وﻧﺸﺎط ﻣﺴﺘﻘﺒﻼت 
أظﮭﺮت زﯾﺎدة أﻛﺒﺮ  ،ﺑﺮوﺗﯿﻨﺎت ﻣﺼﻞ اﻟﻠﺒﻦ وأﺟﺰاءھﺎ ﺑﺬات اﻟﻮﻗﺖ ﻣﻊ ھﺮﻣﻮن اﻹﻧﺴﻮﻟﯿﻦﻋﻨﺪ إﺿﺎﻓﺔ ،ذﻟﻚ
 )stsinogatna(ﻣﻦ ﺻﺤﺔ ھﺬه اﻟﻨﺘﺎﺋﺞ ﺑﺎﺳﺘﺨﺪام ﻣﻀﺎدات  ﺪﻟﻨﺸﺎط ﻣﺴﺘﻘﺒﻼت ھﺮﻣﻮن اﻹﻧﺴﻮﻟﯿﻦ. وﺗﻢ اﻟﺘﺄﻛ
 ﺗﺘﻨﺎﻧﻔﺲ ﻣﻊ اﻹﻧﺴﻮﻟﯿﻦ ﻟﻺرﺗﺒﺎط ﺑﺪﻻّ ﻣﻨﮭﺎ ﺑﻤﺴﺘﻘﺒﻼت )169S(ﻟﻺﻧﺴﻮﻟﯿﻦ. ﺣﯿﺚ أن ھﺬه اﻟﻤﻀﺎدات 
ﺗﻮاﻓﻘﺖ ﺑﺸﻜﻞ راﺋﻊ ﻣﻊ  ،و ﻋﻤﻠﯿﺎت اﻟﻔﺴﻔﺘﺔ TERBاﻟﻨﺘﺎﺋﺞ اﻟﺘﻲ ﺣﺼﻠﻨﺎ ﻋﻠﯿﮭﺎ ﺑﺎﺳﺘﺨﺪام  ،اﻹﻧﺴﻮﻟﯿﻦ.أﺧﯿﺮاً 
ﻧﺘﺎﺋﺞ ﻣﺴﺘﻮى أﺧﺬ واﺳﺘﯿﻌﺎب ﺧﻼﯾﺎ ﺳﺮطﺎن اﻟﻜﺒﺪ ﻟﻠﺴﻜﺮ. وأﺛﺒﺘﺖ ﻛﯿﻔﯿﺔ ﺗﺄﺛﯿﺮ ﺣﻠﯿﺐ اﻹﺑﻞ ﻋﻠﻰ وظﯿﻔﺔ 
اﻹﺑﻞ ﻋﻠﻰ ﺧﻔﺾ اﻟﺴﻜﺮ  واﻟﺬي ﺑﺪروه ﯾﻤﺜّﻞ أول دراﺳﺔ ﺗﻘﻮم ﺑﺈظﮭﺎر ﺗﺄﺛﯿﺮ ﺣﻠﯿﺐ ،ﻣﺴﺘﻘﺒﻼت اﻹﻧﺴﻮﻟﯿﻦ
   ﻋﻠﻰ اﻟﻤﺴﺘﻮى اﻟﺠﺰﯾﺌﻲ ﻟﻠﻤﺴﺎرات اﻟﺪاﺧﻠﯿﺔ ﻟﻠﺨﻼﯾﺎ.
 .ﺟﻠﻮﻛﻮز ،اﻷﻧﺴﻮﻟﯿﻦ ،اﻷﻧﺴﻮﻟﯿﻦ، ﻣﺴﺘﻘﺒﻼت ھﺮﻣﻮن داء اﻟﺴﻜﺮي اﻹﺑﻞ، ﺐﺣﻠﯿ :اﻟﺮﺋﯿﺴﯿﺔﻣﻔﺎھﯿﻢ اﻟﺒﺤﺚ 
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Chapter 1: Introduction 
 
1.1 Diabetes and the insulin receptor 
1.1.1 Definition and characteristics 
Diabetes mellitus (DM) is now recognized as the world’s fastest growing 
chronic condition, and the most common one. With urbanization, easy access to fast 
food, inactive lifestyles and increasing incidence of obesity, its global prevalence has 
increased to 8.8% with 425 million adults (20-79 years) living with diabetes in 2017 
(Figure 1) [1]. The International Diabetes Federation predicts that, following the 
current trend in increase, these numbers are expected to rise to 629 million in 2045. In 
the United Arab Emirates, the prevalence was recorded to be 17.3% in 2017, i.e., 
almost twice the current global average, and is expected to hike up to 23.4% in 2045 
(Figure 2) [1, 2].  
 
Figure 1: Estimated age-adjusted prevalence of diabetes in adults in the world in 
2017 (20-79 years) [1]. 
2 
 
 
 
 
 
Figure 2: Prevalence of diabetes and impaired glucose tolerance (IGT) in the UAE in 
2017 compared to the expected increase in 2045 [2]. 
 
Diabetes is mainly characterized by high blood glucose levels defined as >126 
mg/dl while fasting and >200 mg/dl 2 hours after ingestion of glucose (by the 
American Diabetes Association) [3]. Currently, diabetes has been classified into two 
major types (Figure 3). Type 1 DM (T1DM) is defined as an autoimmune disorder 
where the body attacks its own insulin producing pancreatic β-cells. Type 2 DM 
(T2DM) develops in the later stages of life and is characterized by insulin resistance 
and deficiency in insulin secretion due to progressive loss of β-cell function [3]. It is 
still unclear which event precedes the other, but a popular opinion is that insulin 
resistance develops early in the course of type 2 DM. Pancreatic β-cells then begin and 
continue to overproduce insulin to compensate for this resistance. As the disease 
progresses over the years, there is a gradual impairment of these β-cells and 
consequently, in insulin production, hence, reducing the body’s ability to compensate 
and resulting in hyperglycemia and diabetes [4, 5]. It is difficult to pinpoint an exact 
primary cause of DM, but adiposity, inflammation and genetic predisposition are a few 
key factors that contribute to the development of insulin resistance. The third common 
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type, gestational diabetes, usually develops in the initial stages of pregnancy and 
normally rectifies itself by delivery [3].  
 
 
Figure 3: Differences in pancreatic insulin secretion and insulin receptor activity in 
healthy individuals versus T1DM and T2DM patients [6]. 
 
Hyperglycemia does not have any immediate harmful effects, but over the 
years, persistent high blood sugar levels can have deteriorating effects on blood vessels 
and organs like kidneys, eyes and heart. The pathophysiology of diabetes is complex 
and involves many biological processes. For majority of diabetics, in addition to 
insulin therapy, more than one drug is often used to combat different aspects of the 
disease and maintain glucose homeostasis. Apart from maintaining a healthy lifestyle 
and diet, effective clinical management of diabetes involves the careful selection of 
drugs that complement each other and minimize the risk of negative side effects such 
as hypoglycemia. Consistent control of blood glucose levels in patients with insulin 
dependent diabetes effectively delays and slows down the development of 
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complications like diabetic retinopathy and nephropathy [7]. As research uncovers 
more and more about the pathogenic complexity of diabetes, there is an ensuing 
increase in the search for better and easier treatment options. 
1.1.2 Insulin receptor and its signaling pathways 
Insulin is a 51 amino acid long anabolic hormone secreted by β-cells in the 
Islets of Langerhans of our pancreas in response to rises in blood sugar levels. 
Discovered almost a hundred years ago, it is most famously known for being the key 
player in glucose and lipid homeostasis in the body [8]. In broad terms, insulin 
promotes the uptake and storage of fuel as glycogen and fats, and prevents breakdown 
of stored fuel [9]. Insulin is initially synthesized in the pancreas as a 110 amino acid 
polypeptide called pre-proinsulin. Almost immediately it is transferred to the 
endoplasmic reticulum where it undergoes cleavage and loses its signal peptide to form 
proinsulin [10]. Finally, a middle fragment of proinsulin is removed by proteolytic 
cleavage leaving us with the two chains of mature insulin (A and B) held together by 
disulphide bridges [11]. Insulin achieves its effects through its human receptor (hIR) 
present in the plasma membranes of its target cells – the most prominent ones being 
hepatocytes, adipocytes, skeletal muscle cells, pancreatic β-cells and neurons [12].  
The hIR belongs to the tyrosine kinase family of receptors (RTK). Together 
along with insulin-like growth factor receptors (IGFR) and the orphan receptor, they 
form the IR subfamily. All receptors in the IR family are synthesized as one protomer 
protein which then is proteolytically cleaved to form α and β polypeptide chains. For 
the hIR, these chains are finally assembled into disulfide linked homodimers where 
each monomer is the αβ heterodimer. This αβ monomer is coded for by a gene with 22 
exons. After translation, the pre-mRNA undergoes alternative splicing of exon 11 to 
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create two variants of the hIR without and with the exon; IR-A and IR-B respectively. 
The α subunit of hIR is entirely extracellular and contains the ligand binding domains 
of the receptor. Meanwhile, the β subunit spans the plasma membrane once and then 
constitutes the cytoplasmic subunit, possessing its characteristic tyrosine kinase 
domain [13]. 
 
 
Figure 4: Schematic representation of the Akt/PI3K and MAPK/ERK pathways 
initiated by the insulin induced activation of the hIR. Adapted from [4]. 
 
When insulin binds to α subunit, it causes a conformational change in the 
receptor bringing the two β subunits together in the plasma membrane. This 
consequently allows autophosphorylation of hIR at specific tyrosine residues and 
activation of its kinase activity. We know now that the downstream signaling pathways 
initiated by insulin binding to the hIR cannot be explained as a single line of events 
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one preceding the other, but as a complex and integrated network involving branching 
out at several steps and crosstalk between pathways arising from hIR as well as other 
receptors. The major two pathways by which the hIR controls its metabolic and 
mitogenic effects are Akt/protein kinase B (PKB) pathway and ERK/mitogen-
activated protein kinase (MAPK) pathway respectively (Figure 4). These pathways 
begin with the recruitment and subsequent activation of the scaffolding proteins, 
insulin receptor substrate protein (IRS) and Shc to the hIR via their phosphotyrosine 
binding (PTB) domains. In the PKB/Akt pathway, phosphoinositide 3-kinase (PI3K) 
bind to IRS, via its SH2 domain [14, 15]. Here, the IRSs do not contain any intrinsic 
kinase activity, but act as scaffolds to bring PI3K close and allow their phosphorylation 
by hIR. PI3K then activates protein dependent kinase 1 (PDK1) which in turn activates 
PKB/Akt. Activation of PKB is responsible for the mediation of major metabolic 
effects of insulin such as increase in glucose uptake by translocation of glucose 
transporter 4 (GLUT4) from cytoplasmic vesicles to the plasma membrane, and also 
activation of glycogenesis [9, 16]. Glucose transport proteins like GLUT4 help in 
uptake of extracellular glucose from the blood to inside the cell via an ATP 
independent mechanism [15].  
Another signal transduction protein, Grb2 interacts with IRS to initiate the 
ERK/MAPK pathway. Grb2 then phosphorylates Ras which in turn initiates the 
Ras/Raf/MEK cascade leading to the activation of MAP kinases such as p38, c-Jun N-
terminal kinase (JNK) and ERK1/2 [14]. The MAPK/ERK pathway is the mitogenic 
arm of IR signaling and is responsible for gene expression related to cell growth, 
proliferation and differentiation.  Similar to IRS, Shc is another scaffolding protein 
that binds to hIR and is seen to initiate the ERK/MAPK pathway in an IRS independent 
mechanism [14]. 
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1.1.3 IR, insulin resistance and diabetes 
Insulin resistance is the body’s inability to effectively use physiologically 
normal concentrations of insulin to maintain glucose homeostasis. Although insulin is 
a pleiotropic hormone, ‘insulin resistance’ usually refers to its actions on blood glucose 
levels. Everybody with insulin resistance is not diabetic and some can maintain 
glucose homeostasis by compensatory increase in insulin secretion, while most 
patients with both types of diabetes exhibit some level of insulin resistance [17, 18]. 
Moreover in T2DM,together along with obesity, is one of the major risk factors and is 
seen in pre-diabetic patients more than 10 years before the onset of the disease [18, 
19]. 
 The contributing factors for diabetes involve complex interplay between 
environmental and genetic parts. Obesity, inactive lifestyles, stress and excessive 
nutrition are some of the most common environmental triggers. The genetic 
contribution to the development of diabetes is made clear by its heritability. First 
degree relatives of diabetic patients have a much higher risk of developing the diseases 
as compared to the general population [20]. On a genetic basis, diabetes can be 
monogenic, i.e. arise as a result of just one defective gene, or polygenic, where effects 
of several altered genes (mainly involved in insulin signaling and β-cell growth and 
proliferation) add up to create the diabetic phenotype [21].   
Genome wide association studies have identified more than 50 genetic loci 
associated with T1DM , the most studied of these being mutations in HLA genes [22]. 
When it comes to T2DM, these studies have exposed at least 75 different genetic loci. 
However, the reasons for the effects of these mutations are still unknown [23]. There 
are rare monogenic forms of T2DM such as maturity onset diabetes of the young 
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(MODY), but majority of them are polygenic involving mutations at multiple genetic 
loci [23].  
Being the key pathway when it comes to maintenance of glucose homeostasis 
by the hIR, defects related to proteins involved in the metabolic PI3K/Akt signaling 
cascade obviously play an important role in the pathogenesis of insulin resistance. The 
first critical node in this pathway is the hIR itself [15]. More than 60 different 
mutations affecting the hIR have been identified, most of them resulting in diseases 
involving insulin resistance like the Rabson-Mendelhall syndrome, leprechaunism and 
type-A insulin resistance. Some of these variants have been associated with higher risk 
of developing T2DM [24]. Multiple in vitro studies on skeletal muscle cells isolated 
from diabetic patients reveal faults with IR including markedly reduced 
autophosphorylation in response to insulin, lower expression levels and defective 
kinase activity [25–28]. The IRS scaffolding proteins fall next in line in the pathway. 
Decreased tyrosine phosphorylation of IRS1 and IRS2 has been observed in diabetic 
and severely obese patients [25, 28]. It is interesting to note that in mice knockout 
studies with disruption of IRS2, the mice exhibited diabetic phenotype with insulin 
resistance and impaired beta cell secretion of insulin. However, with the disruption of 
IRS1, mice only developed insulin resistance suggesting compensatory increase in 
insulin levels by the pancreatic beta cells [5]. Reduction in tyrosine phosphorylation 
of PI3K is another factor that contributes to insulin resistance in diabetic and 
prediabetic individuals [25, 28, 29]. The next important protein in this signaling 
pathway is Akt. It is now known that mutations in the kinase domain of Akt2 are 
associated with severe insulin resistance and diabetes [15]. Consequent effects of 
defective IRS, PI3K and Akt activation is also seen significant attenuation of GLUT4 
translocation and glucose uptake and utilization by insulin sensitive peripheral 
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tissues[18, 25, 30]. Another cause of ineffective control of glucose levels in the body 
are missense mutations in the insulin hormone gene. It results in the productions of 
structurally abnormal insulin leading to problems in its biological activity and receptor 
binding abilities [31]. 
1.1.4 Therapies targeting the hIR 
Effective maintenance of glucose homeostasis over the years is the most 
effective way to decrease the adverse effects of hyperglycemia on organs such as eyes, 
heart and kidneys. Currently the best method of treatment for this is by administering 
exogenous or insulin analogs to help cope with insufficiency of biologically active 
insulin or impaired activity of the hIR. However, these treatments are not without 
negative side effects. Excessive activation of the insulin induced mitogenic 
MAPK/ERK pathway can cause weight gain and increased risk of cancer development. 
Occasional hyperinsulinemia can lead to hypoglycemic episodes [4, 32]. Additionally, 
these high levels of insulin can lead to an unwanted increase in the activation of other 
cellular processes like increased androgen production by the ovaries [17]. Recent 
research has been focusing on alternative treatments that target the hIR and activate 
only its glucose lowering metabolic pathways without the mentioned side effects [32]. 
A few examples have been discussed below. 
Qiang et al. (2014) reported the discovery of 4548-G05, a metabolite of the 
fungi Chaetomium gracile, and a non-peptidyl insulin mimetic which specifically 
activates the insulin receptor by binding to its extracellular region in the absence of 
insulin [33]. 4548-G05 activates both Akt and ERK signaling pathways downstream 
of the hIR while also increasing glucose uptake. In mouse models of T1DM and 
T2DM, it reduces blood glucose back to normal healthy levels [33]. Another potential 
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candidate is the synthetic insulin mimetic peptide S597 which showed high hIR 
binding affinity and activation of its kinase activity. It partially phosphorylated the hIR 
and exhibited biased agonism by activating the metabolic pathway almost to the level 
of insulin with negligible stimulation of the mitogenic pathway. Even high 
concentrations of S597 only partially stimulated the MAPK/ERK pathway. 
Accordingly, this peptide did not show much effect on cell proliferation [34].   
 Bhaskar et al. (2012) identified a promising candidate, XMetA – a fully human 
monoclonal antibody which is a positive allosteric modulator highly specific to the 
hIR [35]. XMetA binds to hIR with an affinity higher than insulin but causes only 
partially activation of the metabolic Akt pathway (about 40% of what is activated by 
insulin) and does not potentiate the mitogenic MAPK/ERK pathway [35]. It’s 
interesting to note that XMetA does not compete with insulin since it binds to 
completely different site giving it the advantage of being used in conjunction with 
insulin and other current diabetic drugs. Moreover, it takes away the risks associated 
with complete inhibition of natural hormonal mechanisms [36]. In vitro experiments 
in 3T3 cells confirmed consequent glucose uptake after activation of Akt, while in vivo 
experiments in STZ induced diabetic rats , cynomolgus monkeys and rhesus monkeys 
showed that XMetA normalized both  fasting and non-fasting blood glucose levels, 
along with other metabolic indices of diabetes [35, 37–39]. Even in insulin resistant 
diet induced obese mice, XMetA improved fasting glucose as well as insulin tolerance 
[38]. This character offers XMetA the potential of therapeutic use in patients where 
activation of IR by insulin is defective [37]. More excitingly, these positive effects 
come without side effects such as hypoglycemia and weight gain [38]. Another studied 
monoclonal antibody is IRAB-A, identified by Hinke et al.by phage screening assays 
with the IR extracellular domain. Similar to XMetA, in vitro assays using IRAB-A 
11 
 
 
 
 
identified it as an allosteric agonist with specificity to the insulin receptor. It was also 
observed to stabilize ligand binding and also increased sensitivity of the hIR to insulin 
coupled with higher glucose uptake. The same group also identified an hIR antagonist, 
IRAB-B. IRAB-B treated mice showed rapid development of hyperglycemia, sever 
insulin resistance, decreased phosphorylation of Akt, IRS1, glucose uptake as well as 
body weight [40]. As compared to the current methods, IRAB-B shows the potential 
to be a more cost effective and faster way to induce insulin resistance in mammalian 
models to study the pathophysiology of impaired insulin receptors [40]. 
Along with XMetA, Bhaskar et al.(2014,2014) also identified two other 
antibodies that interact with the hIR – XmetD and XMetS [41, 42]. XMetD is a highly 
specific allosteric insulin receptor antagonist. In vitro experiments showed that XMetD 
markedly decreased insulin affinity, IR autophosphorylation as well as downstream 
events including Akt phosphorylation and glucose transport. What’s more is that it did 
not show any effects in the absence of insulin [42]. Most importantly, in mice induced 
with hyperinsulinemic hypoglycemia XMetD treatment returned blood glucose to 
normal levels [42]. XMetS, on the other hand, enhanced the sensitivity of hIR to 
insulin by stabilizing the insulin – receptor conformation by decreasing their 
dissociation rate. Similar to XMetA, XMetS showed biased activity, enhancing the 
activation of only the metabolic or Akt pathway without much effect on the ERK 
pathway [41]. 
The modifications that these treatments cause to hIR signaling patterns are 
hypothesized to be the result of structural modulations to the IR brought about by 
binding to non-orthosteric sites [43]. While the research involving these treatments are 
still in the preliminary stages and not without the possibility of unidentified long term 
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effects, studying the structural mechanisms could bring us closer to understanding the 
working of the IR and also to the development of new therapeutics for diabetes [32]. 
1.2 Camel Milk 
For centuries, in communities that inhabit the drier areas of Asia and Africa, 
CM has been more than just the traditional source of nutrition. Throughout history, the 
therapeutic nature of CM has been reported against multiple diseases like tuberculosis, 
asthma, jaundice and leishmania [44, 45]. Rightfully called ‘the white gold of the 
desert’, CM has come into the research spotlight in the recent years, with scientists in 
different parts of the world uncovering its various medicinal properties including 
antimicrobial, anti-carcinogenic, anti-hypertensive, anti-oxidant and anti-diabetic 
properties [46].  
1.2.1 Chemical composition of CM 
In general, CM is composed of about roughly 80-90% water, 2-4% fat, 3-4% 
protein, 4-5% lactose, along with vitamins and minerals [47]. However, the specific 
percentages of each of the constituents vary based on influence by factors such as 
lactation stage, age of the camel, geographic and seasonal conditions [48]. Compared 
to bovine milk, CM has lower cholesterol and fat content. Moreover, this fat is mainly 
polyunsaturated fatty acids. Its fat globules are also the smallest in size when compared 
to cow, buffalo and goat milk. The smaller size implies a larger surface to volume ratio 
contributing to its easier digestibility [49, 50]. Milk proteins are broadly classified into 
caseins and whey proteins. In CM, caseins constitute about 75% of all protein while 
whey proteins make up the other 25%. The major protein fractions in camel whey are 
immunoglobulins, camel serum albumin, α-lactalbumin, lactophorin A, and 
lactoferrin. In contrast to bovine milk where β-lactoglobulin is the most abundant whey 
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protein, α-lactalbumin is the most abundant camel whey protein. β-lactoglobulin is one 
of primary culprits when it comes to milk allergies and lactose intolerance. Moreover, 
camel whey actually lacks β-lactoglobulins, making it safe even for such patients [51, 
52]. Camel whey also contains high concentrations of antimicrobial proteins and 
immunoprotective bioactive compounds like lactoferrins, immunoglobulins IgG and 
IgM and lysozyme [53]. To add to this exceptional list of benefits, CM is also rich in 
vitamin C, A, D and riboflavin. Additionally, its mineral profile is similar to that of 
human milk with high concentrations of iron, copper, zinc and potassium [48]. 
1.2.2 Antidiabetic properties of CM 
Many previous studies using animal models and humans have shown beneficial 
effects of CM in diabetes by reducing blood sugar, improving pancreatic β-cell 
function, decreasing insulin resistance and improving lipid profiles [54–60]. It has 
been suggested as an adjunct to insulin therapy because it can effectively reduce the 
amount of insulin required by diabetics. One study contended a significant reduction 
(46.15%) in insulin doses required by Type 1 diabetic patients who consumed raw CM 
for 2 years (Figure 5) [61]. In another study conducted in the camel breeding and 
rearing Raika tribe of India, the incidence risk of diabetes was very low in communities 
that regularly consumed camel versus those that did not [62]. It is also known to 
alleviate other pathophysiological effects associated with diabetes such as obesity, 
inflammation, wound healing, diabetic nephropathy and oxidative damage [63–66].  
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Figure 5: Graphical representation of the reduction in mean doses of insulin required 
in T1DM patients consuming CM over the course of 2 years [61]. 
 
While we cannot pinpoint an exact reason for these antidiabetic effects, recent 
studies have identified a few contributing factors. CM contains approximately 3 times 
more insulin like peptide (52 micro unit/L) as compared to bovine milk. Interestingly, 
camel and bovine milk insulin is only one amino acid different from each other, but 
no hypoglycemic activity has been reported yet for bovine milk. Hence, it is more 
plausible that it is not the insulin itself but its cooperation with the other characteristics 
of CM that helps with glucose homeostasis [67]. An important factor here is that CM 
does not coagulate in our stomach’s acidic environment, probably making it easier for 
this insulin-like peptide to be readily absorbed and passed into the blood stream [61]. 
Moreover, certain CM proteins have amino acid sequences that are rich in half cystine 
residues, much like the insulin family of proteins. Another explanation could be the 
unique property of these peptides in CM to be encapsulated by lipid nanoparticles, 
effectively protecting them from proteolysis in the stomach. The fact that CM is rich 
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in zinc could be another contributing factor, since zinc enhances and stabilizes insulin-
IR interaction [68, 69]. 
The antidiabetic nature of CM is the most famous amongst all its medicinal 
values and has been continuously verified by in-vivo studies on both animal models 
and diabetic patients [54, 58, 61, 68]. However, when it comes to the cellular and 
molecular mechanisms behind this effect, we’ve only scratched the surface. Our 
research explores the effects of CWPs and its fractions on one of the primary targets 
in diabetes: the hIR. We have also looked into the subsequent activation of its signaling 
pathways and glucose uptake into cells. 
1.2.3 Molecular and cellular mechanisms of the antidiabetic effects of CM 
While many in vivo studies have proven the hypoglycemic effects of CM, we 
are still in the early stages of defining the responsible molecular mechanisms. These 
anti-diabetic effects cannot be attributed to one CM component. It is rather the result 
of harmonious action of multiple components on different targets in the body. The 
studies discussed below have proven that these targets can not only be those directly 
associated with diabetes such as the IR, pancreatic β-cells and glucose transporters, 
but also factors that contribute to the pathogenesis of diabetes, such as obesity, 
inflammation and oxidative stress (Figure 6) [55, 66, 70–76].  
One study discovered potent dipeptidyl peptidase-4 (DPP4) inhibitory peptides 
in tryptic hydrolysates of CM [70]. DPP4 is a protease that inactivates incretins, i.e., 
glucagon like peptide-1(GLP-1) and gastric inhibitory polypeptide (GIP). Incretins are 
gut hormones released when food containing sugars and lipids travels into the small 
intestine. They signal the pancreas to produce insulin in accordance to the glucose 
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ingested and inhibit the release of glucagon. This is known as the incretin effect. 
Inhibiting DPP4 slows down incretin degradation allowing their effects to last longer, 
consequently increasing insulin secretion [70].  
Additionally, treatment with CM reduced diabetic oxidative stress by 
significantly decreasing free radicals and production of pro-inflammatory cytokines 
like interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) [71]. Diabetes 
(both T1DM and T2DM) is well known to be a chronic inflammatory disease where 
high levels of inflammatory cytokines and continued oxidative stress contribute 
largely to the pathogenesis and also development of complications in diabetes [72, 73]. 
Conversely, CM increased their anti-inflammatory counterparts IL-2 and IL-4 in 
diabetic mice. This could be due to the direct action of CM proteins, like lactoferrin 
and β-casein, which exhibit anti-inflammatory and anti-oxidant properties. However, 
it is also possible that the lowered glycemic levels indirectly diminishes the existing 
inflammation [60, 75]. Additionally, peptic hydrolysis of colostral CM produces 
bioactive peptides with increased antioxidative properties as compared to the milk 
before hydrolysis [74]. ATF-3 expression and phosphorylated protein kinase B (Akt) 
are two other targets studied. High ATF-3 levels are indicative of increased pro-
apoptotic genes, while decreased Akt phosphorylation influences the development of 
diabetes. Treatment with CWPs brings both these factors back to normal levels in 
diabetic mice [71]. It is possible that DPP4 inhibition along with anti-inflammatory, 
anti-apoptotic and anti-oxidant properties is the basis for increased pancreatic insulin 
secretion observed in diabetic patients and animals [55, 75, 76]. After all, inflammation 
and apoptosis of insulin-secreting pancreatic β-cells certainly is a prime event in both 
types of diabetes. 
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A recent in vitro study by A.O. Abdulrahman et al. suggests that CM directly 
interacts with hIR [77]. It weakly activated hIR but significantly increased its 
sensitivity to insulin, suggesting an allosteric mode of action. The study also narrowed 
down the putative agent to a peptide/protein component in the milk whey fraction [77]. 
In the light of this study, our main objective for this thesis was to test the effect of 
CWPs and its fractions on hIR function, and subsequent glucose uptake, in vitro. Direct 
interaction of CM with the hIR opens up the possibilities of positive allosteric 
modulation of other associated receptors such as those specific for  GLP1 , GIP and 
the IGFR, or even negative allosteric modulation of the glucagon receptor [78]. 
 
Figure 6: Probable molecular targets of camel milk components in the cell that could 
help explain its antidiabetic properties [78]. 
 
Among the constituents of CM, lactoferrin (LF) stands out as a potential player 
when it comes to its antidiabetic effects. Associations between LF and glucose 
homeostasis were initially made by Moreno Navarette et al. when they discovered that 
levels of plasma LF are significantly reduced in T2 diabetics with increased insulin 
resistance [79]. They highlighted that LF effects the insulin signaling pathway by 
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potentiating IR-mediated Akt phosphorylation and increasing GLUT4 and IR 
expression on adipocytes [79, 80]. Moreover, literature shows that increased plasma 
LF is associated with decreased expression of inflammatory markers and overall 
adiposity [81, 82]. Both of which are significant risk factors in the pathogenesis of 
diabetes. Plasma LF levels are also inversely related to abdominal as well as overall 
adiposity while consistent oral consumption decreased abdominal visceral fat in men 
[81, 83, 84]. Lastly, it even inhibits the production of several proinflammatory 
cytokines including TNF-α, IL6 and IL 1β [85]. 
Another possible candidate is adiponectin, a metabolic adipokine secreted by 
the white adipose tissue and present in high concentrations in CM. Higher circulating 
adiponectin levels have been correlated with increased insulin sensitivity while 
reduced levels of plasma adiponectin have been commonly observed along with 
insulin resistance, T2DM, obesity and cardiovascular diseases [86, 87]. 
Lastly, as mentioned in some studies above, CM peptides add one more 
category to its potential antidiabetic components. Gastrointestinal digestion of food 
proteins releases and activates encrypted peptides within it. These peptides have, more 
often than not, higher biological activity when compared to the parent protein. In 
general, milk is one of the major sources of food derived bioactive peptides. The 
peptides present in CM hydrolysates, generated by lysis by digestive enzymes, show 
significant DPP4 inhibition, wound healing and anti-obesity properties in the context 
of diabetes [57, 70, 88]. 
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Chapter 2: Hypothesis, Objectives and Approach 
 
We hypothesize that the hypoglycemic properties of CM observed in vivo may 
involve the action of CWPs, its hydrolysates and LF on the intracellular signaling 
pathways mediated by insulin. 
In order to better understand how CWP affects the hIR at the molecular level, 
our objectives were to study these effects on different aspects of IR function in vitro 
as given below: 
1. Pharmocological effect of CWPs, its hydrolysates and LF on the 
intracellular signaling pathways mediated by hIR by studying the 
phosphorylation status of intracellular kinases ERK1/2 and Akt as well as 
IR itself. 
2. Physical association of IR with the substrate protein IRS1 on treatment with 
CWPs, its hydrolysates and LF. 
3. Effect of CWPs, its hydrolysates and LF on the function of glucose uptake 
into the cells via translocation of glucose transporters (e.g. GLUT4) from 
their cytoplasmic vesicles to the plasma membrane. 
Table 1: Objectives and their respective approaches used in this thesis 
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Chapter 3: Materials and Methods 
3.1 Chemicals, reagents and plasmids 
Human insulin and bovine LF was purchased from Sigma Aldrich. The hIR 
antagonist peptide, S961, was a gift from Dr. Lauge Schäffer (Novo Nordisk, 
Copenhagen, Denmark). Camel LF was generously provided by Dr. Elrashdy M. 
Redwan (King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia).The plasmids 
coding for Renilla luciferase-fused hIR (hIR-Rluc) and YFP-tagged IRS1 (IRS1-YFP) 
used for transient transfections in HEK293 cells were kindly provided by Dr. Rasmus 
Jorgensen (Hagedorn Research Institute, Novo Nordisk, Gentofte, Denmark), Dr. 
Tarik Issad (Cochin Institute, Paris, France), respectively. Correct expression of the 
yellow fluorescent proteins (YFP) tagged proteins was verified visually by using 
fluorescence microscopy and by reading light emission at 540 nm using the Tristar 2 
plate reader. The same instrument was used to verify expression of hIR-Rluc by 
measuring light emissions at 480 nm upon the addition of Rluc substrate. 
3.2 Bacterial transformation and plasmid extraction 
The hIR-Rluc and IRS1-YFP plasmids were first dissolved in 50 µL nuclease 
free water. Transformation was carried out using NEB® 5-alpha competent E. coli cells 
(New England BioLabs Inc.) The bacteria and plasmids were mixed together as per 
manufacturer’s instructions. Briefly, after gentle mixing, the plasmid-bacteria mixture 
was incubated on ice for 10 minutes followed by a heat shock for 42 seconds at 45°C 
on the heating block, and then returned to ice for 5 more minutes. Next, 500 µL of 
SOC Outgrowth Medium (New England BioLabs Inc.) was added to each tube and 
incubated for 1 hour at 37°C in the shaking incubator. This was followed by 
centrifugation at 5000 rpm for 5 minutes, after which the supernatant was discarded, 
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and the pellet resuspended in 50-100 µL of SOC medium. This mixture was spread 
evenly onto agar plates containing the antibiotic ampicillin (Sigma) for colony 
selection and incubated at 37°C for 24-36 hours. 
One colony from the transformed plates for each plasmid was picked and 
dropped into 200 mL of LB media supplemented with ampicillin. The resuspended 
colony was grown in liquid culture overnight at 37°C overnight in the shaking 
incubator. The transformed bacteria were pelleted from the suspension culture the next 
day by centrifugation at 6000 rpm for 15 minutes. The pellets were stored at -20°C 
before being used for plasmid extraction. 
Plasmids were extracted from the bacterial pellets using the Qiagen® Plasmid 
Maxi kit following manufacturer’s protocols. Extracted DNA was finally resuspended 
in nuclease-free water and plasmid concentrations were measured using the NanoDrop 
2000 (Thermo Scientific). Plasmid integrity was checked using agarose gel 
electrophoresis. 
3.3 CM collection, fractionation and hydrolysis 
Milk of Camelus dromedarius was kindly provided by Ms. Aysha, (PhD 
student in the College of Science) fresh every week from her local farm (Al Ain, UAE). 
To obtain the whey proteins for cell treatment, whole milk was first skimmed by 
centrifugation at 5000 rpm for 30 minutes at 4°C to remove fat. Caseins were then 
separated out by acid precipitation by bringing the pH down to 4.6 using 1M HCl 
followed by incubation at 37°C for 30 minutes. The sample was then centrifuged again 
for 5000 rpm at 30 minutes at 4°C to precipitate caseins. Clear whey proteins were 
collected (supernatant) and pH adjusted to 7.4 (physiological pH) prior to cell 
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treatment. All CWP hydrolysates were kindly provided by Dr. Sajid Al Maqsood from 
the College of Food and Agriculture, UAEU. 
3.4 Cell culture and transfection 
Both HEK293 and HepG2 cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) (Gibco) supplied with 10% fetal bovine serum and 100 IU/ml 
penicillin, and 100 µg/ml streptomycin (Sigma-Aldrich) at 37°C in 5% CO2. 
Transient transfections were carried out when HEK293 cells were 
approximately 70% confluent in T75 flasks using Lipofectamine 2000 (Invitrogen) as 
per manufacturer’s instructions. Briefly for each flask, plasmids and lipofectamine 
were separately mixed with 1mL Opti-MEM (Gibco) each and incubated for 5 minutes 
at room temperature. The two mixes were then combined and incubated for another 20 
minutes before it was added to the cells in T75 flasks along with DMEM. For BRET 
experiments, each flask was transfected with 7.5 µg hIR-Rluc2.5 µg IRS1-YFP, while 
for sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
western blotting, each flask was transfected with 5 µg of hIR-Rluc.  
Twenty four hours after transfection, cells were harvested using Trypsin-
EDTA (Gibco) and counted with the improved Neubauer chamber. Cells were then 
seeded into 96-well plates at a density of 105 cells per well for BRET, or into 6-well 
plates at a density of 106 cells per well for western blotting experiments. All 
experiments were carried out a total of 48 hours after transfection. 
HepG2 cells endogenously expressing hIR were seeded into 6-well plates at a 
density of 106 cells/well 48 hours prior to the experiment. 
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3.5 Cell treatment and lysis 
HEK293 cells and HepG2 cells transiently and endogenously expressing hIR, 
respectively, were starved in serum-free DMEM overnight in their 6-well plates. Two 
protocols were followed for the treatment: 1) Cells were treated or not with insulin, 
camel and bovine whey proteins, hydrolysates of CWPs and LF (bovine and camel), 
for 5 minutes to observe ERK1/2 and hIR phosphorylation and 10 minutes for Akt 
phosphorylation, at 37°C. The timings for cell treatment were chosen based on the 
kinetics for these two pathways when activated by insulin [77]. 10 minutes was the 
optimum time for Akt accumulation in the cells after treatment with insulin, while the 
peak for ERK1/2 accumulation was at 5 minutes [77]. The same method was also used 
to study the effects of co-treatment of the mentioned treatments with insulin.  2) Cells 
were pre-treated with whole CWPs or its hydrolysates for 60 minutes before the 
addition or not (control) of insulin. In experiments involving the hIR-selective 
antagonist (S961), 1 µM of the antagonist was added along with the initial treatments.  
After treatment, the cells were washed in ice cold PBS followed by 
homogenization, for 90 min at 4°C, with 200 µL/well of ice-cold RIPA lysis buffer 
(Merck Millipore) supplemented with phenylmethylsulfonyl fluoride (PMSF) (Roche) 
and protease inhibitors (Sigma-Aldrich). Cell lysates that were then scraped and 
collected were centrifuged for 15 min at 15000 g (4°C) to remove cell debris. The 
supernatants were stored at -20°C until further use. 
3.6 Protein quantification by BCA assay 
Protein concentrations of the lysates were determined by the BCA assay using 
the BCA Protein Assay Kit (Pierce, Thermo Scientific). 
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3.7 SDS-PAGE and Western blotting 
20 µg of protein from each cell lysates sample was mixed with Laemmli buffer 
(Bio-rad) and heated for 5 minutes at 95°C. The samples were then separated by SDS-
PAGE (225 V for 75 minutes) and transferred to polyvinylidene fluoride (PVDF) (Bio-
Rad) membranes by conventional wet-transfer technique (100V for 90 minutes). 
Transfer was confirmed by staining with Ponceau (Sigma-Aldrich). The membranes 
were then blocked in 5% skimmed milk prepared in PBS (Gibco) containing 0.1% 
Tween 20 (Bio-Rad) (PBST) for 1 hour before moving on to immunoblotting. The 
membranes were incubated overnight in primary antibodies against Akt, pAkt, 
ERK1/2, pERK1/2, IR-β, and pIR-β (Table 2). Anti- rabbit IgG or anti- mouse IgG 
conjugated to horseradish peroxidase (HRP) were used as secondary antibodies as per 
the source of the primary antibodies. Membranes were treated with secondary 
antibodies for 45 minutes before treatment with the chemiluminescent substrate for 
detection (Pierce ECL and SuperSignal West Femto, Thermo Scientific). HRP activity 
was detected by chemiluminescence using the LI-COR C-digit Blot Scanner (LI-COR 
Biosciences.). The whole protocol in also described in Figure 7. All antibodies were 
purchased from Cell Signaling Technology, except the anti-pIR (Tyr1334) (Thermo 
Fischer). 
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Table 2: List of antibodies used and their working dilutions 
Antibody Catalog no. Dilution used 
Akt 9272 1:1000 
pAkt (Ser473) 9271 1:800 
ERK1/2 4695 1:1000 
pERK1/2 
(Thr202/Tyr204) 9106 1:2000 
IR-β 3020 1:1000 
pIR-β (Tyr1345) 3026 1:1000 
pIR (Tyr 1334) 44-809G 1:1000 
Anti-mouse IgG –HRP 7076 1:3000 
Anti-rabbit IgG –HRP 7074 1:3000 
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Figure 7: Schematic representation of cell treatment and western blotting. 
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Figure 8: Schematic representation of cell treatment for BRET assays. 
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3.8 BRET assays 
The BRET assay is a technique that can be used to protein-protein interactions 
in live cells and in real-time (Figure 8). It operates on the principle of resonance energy 
transfer from a bioluminescent donor to fluorescent acceptor based on their proximity. 
When the emission spectrum of the donor overlaps with the excitation spectrum of the 
acceptor, transfer of energy occurs from the former to the latter. Thus, when the two 
proteins are in close proximity (<10 nm), we are able to observe an increase in the 
BRET signal (Figure 9). Transfected HEK293 cells co-expressing hIR-Rluc (BRET-
donor) and IRS1-YFP (BRET–acceptor) proteins were starved overnight in serum-free 
DMEM. Cells were treated with 50 µL/well of respective treatments or PBS (control) 
and incubated at 37°C for 60 minutes. When required, S961 was added along with the 
treatments at this stage. This was followed by removal of treatment and addition of 40 
µL of 2.5 µM coelenterazine h (Promega) prepared in PBS.  BRET measurements of 
emitted light were immediately carried out using the Tristar 2 multilabel plate reader 
(Berthold, Germany) at 480 n and 540 nm. 
29 
 
 
 
 
 
Figure 9 : Principle of the BRET assay (adapted from [89]). 
 
3.9 Glucose uptake assay 
Glucose uptake into non-transfected HepG2 cells was measured using the 
Glucose Uptake-Glo Assay (Promega). Briefly, HepG2 cells that were seeded into 96 
well plates at a density of 105 cells/well were washed with PBS and starved in glucose 
and serum free medium on the day before the experiment. The experiment was started 
by removing the media and adding respective treatments to the wells followed by 
incubation for 60 minutes at 37°C. The stimulants were then removed and 25 µL of 
freshly prepared 1mM 2-deoxyglucose was added to each well. After 10-15 minutes 
at room temperature the reaction was stopped, and cells lysed using provided buffers. 
50 µL/well of freshly prepared 2-deoxyglucose-6-phosphate detection reagent 
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containing Ultra-Glo™ Recombinant Luciferase was added before incubating the plate 
for 15-60 minutes at room temperature. The luciferase activity was measured at 15-
minute intervals using the Glo-Max® Discover Microplate reader. 
3.10 Data and statistical analysis 
All BRET, western blotting and glucose uptake experiments were carried out 
in triplicates. Bands visualized after western blotting were quantified by taking the 
ratio of phosphorylated protein over the respective total protein to compare the rates 
of phosphorylation among samples. Quantification of bands and graph generation were 
carried out using Image Studio software, Version 5.2.BRET ratios were calculated as 
light emissions at 540 nm over 480 nm. From this, the ligand induced BRET was 
obtained by subtracting the control (only PBS treated cells) values. Next, all the values 
were normalized by taking the insulin induced positive control as 100%. Graphs were 
plotted using GraphPad Prism software. Statistical analyses were performed with two-
way ANOVA and Tukey's multiple comparisons test to determine statistically 
significance between the different conditions. ****p-value < 0.0001, ***p-value < 
0.001, ** p-value < 0.01, * p-value < 0.05, and ns p-value > 0.05. 
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Chapter 4: Results 
4.1 Successful CM whey proteins (CWPs) fractionation and hydrolysis 
After removing the fat and casein fractions from fresh CM, we ran them on an 
SDS-PAGE gel to confirm the presence of required fractions as well the integrity of 
whey proteins. Coomassie staining of the gel revealed clear single bands at around 80 
kDa in the lanes for camel and bovine LF signifying the presence of unadultered and 
intact LF. Camel and cow whey proteins showed in intact bands as well (Figure10). 
 
Figure 10: Coomassie blue staining of the gel confirming the presence of CWPs and 
LFs in the samples. 
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4.2 CWPs activate Akt and ERK1/2 pathways in HEK293 and HepG2 cells 
As stated above, CM has been reported to have significant anti-diabetic effects 
in many in vivo studies. Therefore, we attempted to link such interesting properties of 
CM with more integrated cell responses and molecular pathways using two different 
cells models, HepG2 cells endogenously expressing hIR and HEK293 cells transiently 
expressing or not hIR. For this, we investigated the functional activity of CWPs on the 
two major intracellular signaling pathways, Akt and ERK1/2 phosphorylation, known 
to be the key hIR-mediated downstream signaling involved in glucose uptake and 
homeostasis. As shown in Figure 11A, insulin (1 µM) used as a positive control 
significantly increased Akt and ERK1/2 phosphorylation in both HEK293 and HepG2 
cells indicating the activation of hIR and validating the experiment. Interestingly, 
CWPs (1 mg/ml) also strongly induced Akt and ERK1/2 phosphorylation in HEK293 
and HepG2 cells similarly to insulin action (Figure 11A). The overexpression of hIR 
in HEK293 seems to increase both insulin- and CWPs-mediated response compared 
to mock HEK293 cells (Figure 11A). These data demonstrate the functional activity 
of camel milk proteins on Akt and ERK1/2 signaling pathways that might explain the 
hypoglycemic effect of camel milk. 
Next, we examined the biological activity of CWPs upon in vitro proteolysis 
into heterogeneous peptide fractions. The rationale behind this was to mimic the 
obvious gastric proteolysis of CM proteins after its consumption. For this, we 
subjected CWPs to enzymatic digestions using the key gastric and pancreatic 
proteolytic enzymes, trypsin, chymotrypsin and pepsin and we then tested the effect 
of their respective hydrolysates at 1 mg/ml on Akt phosphorylation in HEK293 cells. 
As shown in Figure 11D, while trypsin hydrolysate fully lost its activity the 
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chymotrypsin and the pepsin ones were still functional like insulin and CWPs. This 
indicates that CWPs hydrolysis by chymotrypsin and the pepsin did not impair the 
biological activity of the proteins suggesting the existence of biologically active 
peptides contained in such fractions. 
 
Figure 11: CWPs activate Akt and ERK1/2 pathways in HEK293 and HepG2 cells. 
HEK293 cells transiently over-expressing hIR or not, and HepG2 cells endogenously 
expressing hIR showing phosphorylation of Akt and ERk1/2 on treatment with insulin 
or CWPs. A) pAkt, Akt, pERK and ERK bands visualized after western blotting. B) 
and C) The fold increase in phosphorylation of Akt and ERK1/2 (respectively) over 
the control. 
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4.3 Effects of LF on Akt and ERK1/2 pathways in HEK293 and HepG2 cells 
Following this, we investigated the effects of two potential candidates in 
CWPs: LF and adiponectin, on the Akt and ERK pathways. Both camel and bovine LF 
potentiated an increase in the phosphorylation of ERK1/2 that seemed to increase with 
over expression of hIR in HEK293 cells. However, the increase was more pronounced 
by bovine LF (Figure 12). Moreover, bovine LF also induced the phosphorylation of 
Akt, which was not evident when both HEK293 and HepG2 cells were treated CMLF 
(Figure 12). In HepG2 cells, however, CMLF potentiated ERK phosphorylation more 
than bovine LF.  The results with bovine LF are consistent with previously published 
research that showed that LF increases insulin induced Akt phosphorylation [79, 80]. 
Adiponectin did not show any activation of both pathways and was not continued with 
for further investigations (data not shown). 
 
Figure 12: Effects of LF on Akt and ERK1/2 pathways in HEK293 and HepG2 cells. 
Western blotting data of cells lysates from HEK293 cells transiently over expressing 
hIR or not, and HepG2 cells endogenously expressing hIR showed significant 
phosphorylation of Akt and ERK1/2 when treated with CWPs, bovine milk whey 
proteins (BWPs) and bovine LF. Camel LF on the other hand, showed significant 
activation of ERK1/2 pathway and only very slight phosphorylation of Akt. 
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4.4 Positive effects of CWP hydrolysates on Akt and ERK1/2 pathways in 
HEK293 and HepG2 cells 
Next, we profiled the most potent peptides obtained from pepsin hydrolysis of 
the raw CWPs for their biological activity on Akt and ERK1/2 pathways. These 
peptides are designated as P3:1, P5:1, P5:2, and P6:2 and used at 1 mg/ml along with 
the original CWPs (1 mg/ml). This dose was selected based on dose response studies 
of CWP and its hydrolysates on cells, showing maximum phosphorylation at 1mg/ml 
(data not shown). Among these peptides, P3:1, P5:1, and P5:2 showed to different 
extents, a stronger response on both Akt and ERK1/2, while P6:2 only induced a weak 
response with a relative stronger action of the peptide fractions on ERK1/2 compared 
to Akt pathway (Figure 13). Akt and ERK phosphorylation was observed in mock 
HEK293 cells as well as HepG2 cells with a few differences in the effect of the 
different peptide fractions in the two cell types. HEK cells overexpressing hIR 
however, stimulated only ERK phosphorylation and did not show any significant 
phosphorylation of Akt on treatment with the peptides (Figure 13). Together, these 
observations demonstrate the biological activity of peptide fractions obtained from 
pepsin hydrolysis of the whole CWPs and further confirm the existence of bioactive 
peptides in CWPs. 
36 
 
 
 
 
 
Figure 13: Positive effects of CWP hydrolysates on Akt and ERK1/2 pathways in 
HEK293 and HepG2 cells. These western blots show the successful phosphorylation 
of Akt and ERK1/2 by 3 out of the 4 peptic hydrolysates of CWP tested on mock 
HEK293 cells and HepG2 cells endogenously expressing hIR. HEK293 cells over 
expressing hIR showed only ERK phosphorylation. 
 
4.5 Positive effects of CWPs and their hydrolysates on hIR activity studied by 
BRET in HEK293 cells 
Next, we wanted to link our data on Akt and ERK1/2 with the putative effects 
of the raw CWPs and their peptide fractions on the activation of the hIR transiently 
expressed in HEK293 cells. For this, we used BRET technology as previously 
described. The assay measures in live cells the physical recruitment of IRS1-YFP 
protein to hIR-Rluc upon its activation by insulin and camel milk fractions as described 
in the methods sections (Figure 9). As a validation of the BRET assay, insulin 
promoted a nice dose-dependent increase in the BRET signal between hIR-Rluc and 
IRS1-YFP with the expected potency (EC50 value of 386.52± 32.34 nM, n=5) (Figure 
14A). Next, we examined the effect of a single stimulation on BRET signals in cells 
upon their incubation 60 minutes at 37ºC with either insulin (1 µM), CWPs (1 mg/ml), 
or the different peptide fractions (1 mg/ml). As shown in Figure 14B, CWPs and their 
peptide fractions clearly increased the BRET signal between hIR-Rluc and IRS1-YFP 
and this to different extent (50 - 75%, p<0.001, n=5-8) compared to insulin used as a 
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positive control. These observations suggest a positive pharmacological effect of 
camel milk fractions on hIR activity. To further confirm these observations, we 
performed dose-response analysis showing a significant dose-dependent BRET 
increase with CWPs (Figure 14C) as well as the different peptide fractions (Figure 
14D). Together these results reveal positive effects of CWPs and their peptide fractions 
on hIR activity suggesting either a direct or an indirect on hIR in HEK293 cells that 
may explain our data on Akt and ERK1/2 pathways shown in Figure 11 and 13. 
 
Figure 14: Positive effects of single treatments of CWPs and their hydrolysates on hIR 
activity studied by BRET in HEK293 cells. BRET experiments carried out in 
transfected HEK293 cells showing positive stimulation of the IR and subsequent 
recruitment of IRS1. A) Dose response of insulin, B) BRET response after 1 hour 
treatment of single dose of insulin (1uM), CWPs or its fractions (1mg/ml), C) Dose 
response of CWPs, D) Dose response of peptic hydrolysates of CWPs. 
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Figure 15: Positive effects of co-treatment of insulin with CWPs or their hydrolysates 
on hIR activity studied by BRET in HEK293 cells. BRET experiments carried out in 
transfected HEK293 cells showing significant increase in insulin-induced stimulation 
of the IR and subsequent recruitment of IRS1. A) Co-treatment of cells with CWPs or 
its hydrolysates with single dose of insulin (1µM), B) Dose response of insulin on cells 
pre-treated with CWPs or its fractions, C) Dose response of CWPs, D) Dose response 
of peptic hydrolysates of CWPs. 
 
We also tested the effect of the combined stimulation of the cells co-expressing 
hIR-Rluc and IRS1-YFP with insulin (1 µM) in the presence of 1 mg/ml of either 
CWPs or their peptide fractions in the aim to reveal any allosteric effects on hIR. This 
was based on the previous study reporting a positive allosteric action of camel milk on 
hIR activity [77]. As shown in Figure 15A, the co-treatments with CWPs and their 
peptide fractions significantly potentiated, to different extent (60 - 100%, p<0.001, 
n=5-8), the insulin-mediated BRET signals. Such a positive effect was also confirmed 
on insulin dose-response showing a significant increase in both the efficacy (Emax, 
39 
 
 
 
 
p<0.001, n=5-8) and the potency (given in Log EC50, p<0.001, n=5) of insulin (Figure 
15B) (Table 3) revealing a positive allosteric action of CWPs and their peptide 
fractions on hIR. Additionally, we used the angiotensin receptor (AT1R) conjugated 
to Rluc as BRET donor and its downstream signaling protein, Gαq conjugated to 
Venus (a variant of YFP) as a negative control for this experiment. As shown in Figure 
15C and 15D, single treatment of CWPs and its hydrolysates as well as their co-
treatment with Angiotensin II (Ang II) did not significantly increase the BRET signal 
compared to the control. This confirms that CWPs will not randomly potentiate any 
receptor in the cell. 
To demonstrate this positive allosteric action on hIR, we also examined the 
effect of the co-treatment on ERK1/2 response in cells pre-treated or not with either 
CWPs (1 mg/ml) or the different peptide fractions (1 mg/ml) for 60 minutes at 37ºC 
before their stimulation with insulin (1 µM) for 5 minutes at 37ºC. As shown in Figure 
16, the co-treatment with CWPs and the different peptide fractions strongly potentiated 
the insulin-mediated ERK1/2 phosphorylation and this was consistent with our BRET 
data shown in Figure 15. Together these results also reveal a positive allosteric action 
of CWPs and their peptide fractions on hIR activity in addition to their insulin-
independent effects. 
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Figure 16: Positive effects of co-treatment of insulin with CWPs or their hydrolysates 
on ERK1/2 phosphorylation in HEK293 cells. In HEK293 cells transiently over 
expressing hIR A) pre-treatment of cells with CWPs and their hydrolysates for 60 
minutes followed by 5 minutes with insulin and B) Co-treatment of cells with insulin 
and CWPs and their hydrolysates for 5 minutes, showed increase in ERK1/2 
phosphorylation to almost the levels of insulin. 
 
4.6 The positive allosteric effect of CWPs and their peptide fractions on hIR 
depends on its activation by insulin 
In order to characterize the positive allosteric action of CWPs and their peptide 
fractions on hIR activity, we examined the effect of the hIR-selective peptide 
antagonist, S961, as previously reported [90]. For this, BRET measurements were 
performed in HEK293 cells transiently co-expressing hIR-Rluc and IRS1-YFP and 
treated or not with either insulin (1 µM), CWPs (1 mg/ml), or the different peptide 
fractions (1 mg/ml), in the absence (control) or presence of 1 µM of S961. As shown 
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in Figure 17A, the different treatments significantly elicited BRET increase between 
hIR-Rluc and IRS1-YFP (p<0.001, n=3) further confirming the positive action of 
CWPs and their peptide fractions on hIR activity. In addition, S961 treatment 
drastically inhibited insulin-mediated BRET by∼80 % compared to the control 
(p<0.0001, n=3) indicating that the increase in the BRET signal indeed reflects hIR 
activation by insulin. However, S961 had no significant effects on the BRET signals 
promoted by CWPs and the different peptide fractions (Figure 17A). Next, to confirm 
our positive BRET data indicating the potentiation of IR, we analysed the 
phosphorylation status of the IR. As we expected, IR was phosphorylated by the whey 
proteins as well all the hydrolysates (Figure 18A) further supporting the suggestion 
that CWPs interact directly with the hIR in some way.  
In the co-treatment protocol where cells were treated with insulin in the 
presence of either CWPs or the different peptide fractions, a very strong potentiation 
in the BRET signals was observed compared to the control (p<0.0001, n=3) further 
confirming the positive allosteric action on hIR (Figure 17B). More interestingly, the 
treatment with S961 drastically abolished the potentiation of the BRET signals 
(p<0.0001, n=3) (Figure 17B) and the remaining partial response reflects the direct 
effects of CWPs and different peptide fractions on hIR similarly to what we obtained 
in Figure 17A. Adding to this result, we also observed that co-treatment of CWPs with 
insulin increased phosphorylation of hIR (Figure 18B). More importantly, this 
phosphorylation was completely blocked in the presence of S961, further proving that 
the increase in sensitivity to insulin observed in BRET is through the insulin receptor. 
 Moreover, we initially used two different pIR antibodies recognizing two 
different phosphorylated tyrosines in the hIR. Interestingly, although insulin 
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phosphorylated both these tyrosine residues, CWPs phosphorylated only one (i.e., Tyr 
1345) indicating differential phosphorylation of the receptor by CWPs (Figure 18C). 
This could be an explanation for the increase in IR potentiation when cells were pre-
treated with CWPs before challenging them with insulin. For all further experiments 
with the hydrolysates, anti-pIR (Tyr 1345) was used. 
  
Figure 17: The positive allosteric effect of CWPs and their peptide fractions on hIR 
depends on its activation by insulin. These graphs show the differences in BRET 
potentiation with A) single treatment of CWPs and its hydrolysates with and without 
the hIR antagonist S961 B) co-treatment of CWPs and its hydrolysates with insulin in 
the presence and absence of S961. 
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Figure 18: The phosphorylation of IR showing that the positive allosteric effect of 
CWPs and their peptide fractions depends on its activaion by insulin. In HEK293 cells 
overexpressing hIR: A) Single treatment by insulin, CWPs or its hydrolysates results 
in phosphorylation of IR. B) Pretreatment with CWPs or its hydrolysates followed by 
treatment with insulin (1 uM) leads to increase in phosphorylation of IR and this is 
blocked by S961. C)  Differential phosphorylation of the insulin receptor by CWPs. 
 
4.7 Positive effects of CWPs and their hydrolysates on glucose uptake in HepG2 
cells 
In order to translate our BRET and kinase (Akt and ERK1/2) phosphorylation 
data into more integrated cell response and to make a link with the hypoglycemic 
properties of camel milk demonstrated in many in vivo studies, we also examined the 
effects of CWPs and different peptide fractions on glucose uptake in native/non-
transfected HepG2 cells. As shown in Figure 19, unexpected in contrast to insulin all 
the other treatments significantly (p<0.0001, n=5) and to different extent promoted 
glucose uptake in HepG2 cells. HepG2 cells being liver cells predominantly express 
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glucose transporter 2 (GLUT2), while insulin induces glucose uptake through GLUT4 
[91, 92]. Glucose uptake through GLUT2 is insulin independent. Together, this could 
explain the low levels of glucose uptake into insulin treated HepG2 cells. 
 
Figure 19: Positive effects of CWPs and their hydrolysates on glucose uptake in 
HepG2 cells. CWPs and its hydrolysates stimulated glucose uptake into HepG2 cells 
endogenously expressing the hIR. 
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Table 3: Emax and Log EC50 values determined from the different single and 
combined treatments with insulin, CWPs, and the different peptide fractions (as shown 
in Figure 14C and Figure 15B). 
 
Treatment Emax (%) 
in single 
treatment 
Emax (%) 
in combined 
treatment 
Log EC50of insulin 
in combined 
treatment 
Insulin 
(Control) 
100 100 -6.28 ± 0.07 (n=5) 
CWPs 80 ± 8 (n=8) 184± 18 (n=8) -7.13 ± 0.14 (n=5) 
P3:1 67 ± 13 (n=5) 183± 19 (n=5) -7.29 ± 0.34 (n=5) 
P5:1 51 ± 8 (n=8) 162 ± 17 (n=8) -7.63 ± 0.35 (n=5) 
P5:2 76 ± 16 (n=5) 188± 23 (n=5) -7.50 ± 0.34 (n=5) 
P6:2 70 ± 9 (n=8) 157± 19 (n=8) -7.46 ± 0.39 (n=5) 
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Chapter 5: Discussion and Conclusion 
The antidiabetic nature of CM has been proved time and again by multiple in 
vivo studies in both animal models of the disease and diabetic humans. As mentioned 
earlier, a recent study revealed that raw CM significantly increased the recruitment of 
substrate proteins involved in insulin- induced downstream signaling pathways, to the 
hIR [77]. This potentiation was narrowed down to be the action of a component in the 
whey fraction of CM. Due to its obviously major role in glucose homeostasis, we 
hypothesized that this effect was linked to the activation of hIR by CWPs. To answer 
our question, we looked into effect of CWPs on induction of different mechanisms that 
are normally carried out by insulin for glucose homeostasis via the hIR: 
phosphorylation Akt and ERK1/2, physical association of IRS1 to hIR and increase in 
glucose uptake. The in vitro effects of CWPs, its hydrolysates, LF and adiponectin 
were studied on these three parameters. CWPs and its hydrolysates clearly potentiated 
Akt and ERK phosphorylation to levels that were comparable to insulin.  These two 
proteins play key roles in two major pathways activated by the insulin receptor, Akt in 
the metabolic pathway and ERK1/2 in the mitogenic pathway. This was true even for 
the peptic and chymomtryptic hydrolysates of CWP as well as the different peptide 
groups obtained after peptic hydrolysis and bovine LF. CMLF however, was only seen 
to activate the ERK1/2 signaling pathway, and to a lower extent than bovine LF. It is 
possible that the higher activity of bovine LF when compared to CMLF is due to the 
fact that bovine LF used here was commercially purchased, while CMLF was isolated 
in the university labs. However, we can also speculate that CMLF when given to cells 
as pure treatment does not elicit the same response as when it enters the body as part 
of whole CM. As mentioned before, a number of factors like the pH and stability of 
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CM along with the encapsulation of milk proteins by lipid nanoparticles, all contribute 
to the better bioavailability of CM proteins once ingested [61, 67].  
It’s important to note here that since the phosphorylation of Akt and ERK are 
not events that are exclusive to hIR activation and is possible through other receptors, 
we cannot use these results to confirm activation of hIR or the binding of CWPs and 
its hydrolysates to the hIR.  
Stepping one step closer to hIR activation, CWPs, its hydrolysates and LF also 
showed increased BRET signals (upto 75% that of insulin) signifying the physical 
association of hIR with IRS1. IRS1 is an important scaffolding protein involved in 
both the metabolic Akt and mitogenic ERK pathways induced by insulin through the 
hIR. It is the first intracellular protein that interacts with the hIR upon activation[14, 
15]. The consequent increase in glucose uptake into HepG2 cells confirms the 
intracellular translation of these signals into responses. 
Excitingly, when we co-treated hIR expressing cells with insulin along with 
CWPs or their hydrolysates, we witnessed a 60-100% jump in insulin induced -BRET 
signals. This is consistent with the observation from the previously mentioned study 
by A.O. Abdulrahman and colleagues which suggested a positive allosteric action of 
CM on hIR [77].  Comparing dose response studies of insulin with and without CWPs 
or its hydrolysates, we can clearly see that these proteins and peptides increase both 
the potency and efficacy of insulin. Fractions of CWP increased insulin induced 
recruitment of IRS1 to hIR even at saturating doses of insulin.  Additionally, these 
signals were higher than those achieved at saturating single doses of CWPs or their 
hydrolysates. Moreover, this view was strengthened further when blocking the hIR 
with the antagonist S961 significantly reduced insulin–induced BRET but had almost 
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no effect on that induced by any of the CWP fractions. Blocking of IR in cells treated 
with both insulin and CWPs remarkably diminished the insulin effect in the treatment 
and brought them back to the single treatment levels. All of these points suggest an 
allosteric mode of action of action of CWPs and their peptide fractions on hIR. The 
binding of insulin to the extracellular domain of the receptor, changes and stabilizes 
the conformation of the receptor in such a way that enables its intracellular kinase 
domains to undergo successful autophosphorylation and initiate signaling. We know 
now that the different ligands can exist for a single receptor and they can stabilize and 
potentiate the receptor to different extents and/or to be selective to certain downstream 
pathways [93]. In this scenario, it is possible that the allosteric binding of CWPs to the 
hIR stabilizes the insulin-hIR complex in a conformation that enables better interaction 
with downstream proteins, higher affinity to insulin and/or a lower dissociation rate of 
the ligand-receptor complex (Figure 20). A similar model of activation of the hIR is 
seen in XMetS, an allosteric antibody to the hIR [41]. These results also support the 
finding by Agrawal et al. (2011) where the amount of insulin required by diabetics 
considerably reduced over the course of 2 years if they were consuming camel milk 
[61]. Increased potency with co-treatment of insulin with CWPs or its fractions implies 
that, in the presence of CWP, a smaller quantity of insulin is required to achieve the 
same effect. 
It is important to note here that this allosteric effect of CWPs and its 
hydrolysates is in addition to the insulin-independent effects observed initially. While 
this study indeed postulates some degree of direct activation of the insulin receptor by 
CWPs, we cannot rule out the possibility that CWPs also have some indirect effects 
on the hIR and its related pathways. It is possible that it is potentiating downstream 
signaling targets in insulin induced hIR signaling pathways via activation of other 
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receptors. Another possibility is that CWPs affect completely different pathways that 
contribute to glycemic control via the activation of other receptors. Receptors like 
IGFR and cell surface receptors for glucagon, incretins and cytokines are some 
potential receptor candidates for this cause [78] (Figure 20).  
Another point to note is that in the previously mentioned study by A.O. 
Abdulrahman et al. (2016), CM proteins only increased the recruitment of Grb2 to hIR 
and not IRS1 [77]. On the contrary, our study shows significant potentiation through 
hIR-IRS1 interaction. These differences can perhaps be reconciled by the fact that 
differences in storage of the milk, lactation stage, breed and living environment of the 
camels can affect the concentration of proteins in the milk [46]. Throughout the course 
of this thesis work, CWPs were fractionated from fresh CM every week. Though the 
source of CM was always the same farm, minimal differences were observed in Akt 
and ERK phosphorylation levels and also in the IR activation levels seen in BRET 
experiments with different preparations of CWPs. These differences can be attributed 
to the reported changes in CM protein levels that come along with changes in seasons 
and changes in lactation periods [46]. The final values and results are averages of three 
or more distinct experiments.  
Increasing the sensitivity of hIR via allosteric binding is an exciting possibility 
that comes with the potential to provide a new door for drug development strategies 
for diabetes. Studying the structural and physical properties of these interactions will 
help us understand the molecular interactions associated with hIR signaling better. 
Since they potentially bind to a site completely different spatially and structurally to 
that of insulin, allosteric modulator’ actions can be more specific to the receptor than 
that of the orthosteric ligand. This is because sequence similarity in these sites is more 
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unlikely across receptors from the same family (for example: IR and IGFR) [36]. 
Therapies that increase the sensitivity of the hIR can reduce the requirement for 
exogenous insulin and hence, also be less likely to induce hyperinsulinemia. When 
therapies like this are started at early stages of diabetes, they may even postpone or 
nullify the need for exogenous insulin by preserving β cell function in the pancreas 
[41]. 
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Figure 20 : Putative model of the action of CWPs on the IR. 
A) Allosteric mode of action by direct interaction with the IR, B) Indirect effects on 
IR activated pathways via another receptor (adapted from [77]). 
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Chapter 6: Future Directions 
This research definitely takes us one step closer to understanding the molecular 
mechanisms that are responsible for the hypoglycemic effects of CM observed in vivo. 
Although, it will be beneficial to investigate the action of CWPs and its hydrolysates 
on other receptors involved in glucose homeostasis, such as the IGFR, glucagon and 
incretin receptors. Another interesting target would be the IR-IGFR hybrid receptors, 
since they respond to insulin and IGF in ways that are different to their homodimeric 
counterparts. Additionally, our study prioritized only a subset of the hydrolysates 
produced by CWPs on gastric digestion. Further investigations are required to assess 
the effects of hydrolysates generated by different enzymes/ combinations of enzymes 
in different conditions (e.g. time, pH) to bring us closer to actual stomach conditions. 
 It is also essential to confirm the in vitro effects of CWP hydrolysates in in 
vivo systems such as diabetic mice models. In vitro studies rule out the physiological 
effects of persistent high blood glucose levels in the environment. The cancerous 
characteristics of established cell lines like HepG2 cells can lead to altered results [94]. 
These effects may very well contribute to differences in the hypoglycemic activity of 
camel milk in vivo.  
Finally, sequencing and studying the peptides obtained after peptic hydrolysis 
of CWP is another possibility that could help us move further. Protein modeling and 
binding studies of these hydrolysates can provide us with better insights into the 
working and activation of the IR. Above all, it can give us a new perspective on 
modulation of IR signaling. 
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